Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999) by Gales, Ana Cristina et al.
S104 • CID 2001:32 (Suppl 2) • Gales et al.
S U P P L E M E N T A R T I C L E
Emerging Importance of Multidrug-Resistant
Acinetobacter Species and Stenotrophomonas
maltophilia as Pathogens in Seriously Ill
Patients: Geographic Patterns,
Epidemiological Features, and Trends in the
SENTRY Antimicrobial Surveillance Program
(1997–1999)
A. C. Gales,1,4 R. N. Jones,1 K. R. Forward,2 J. Lin˜ares,3 H. S. Sader,4 and J. Verhoef5
1University of Iowa College of Medicine, Iowa City, Iowa; 2Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada; 3Hospital de
Bellvitge, Barcelona, Spain; 4Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 5Utrecht University,
Utrecht, the Netherlands
As part of the SENTRY Antimicrobial Surveillance Program, a total of 1078 Acinetobacter species and 842
Stenotrophomonas maltophilia isolates were collected between January 1997 and December 1999 from 5 geographic
regions (Canada, the United States, Latin America, Europe, and the Asia-Pacific). The frequency of infections
(by geographic region and body site), including those due to imipenem-resistant Acinetobacter species and
trimethoprim-sulfamethoxazole (TMP-SMZ)–resistant S. maltophilia, was evaluated. The possibility of seasonal
variations in bloodstream infections caused by Acinetobacter species was studied, as was the activity of several
therapeutic antimicrobials against all strains. Acinetobacter species and S. maltophilia were most frequently
associated with pulmonary infections, independent of the region evaluated. In contrast, patterns of antimicrobial
resistance markedly varied among distinct geographic regions, especially for nosocomial isolates. Although the
carbapenems were the most active antimicrobials against Acinetobacter species, nearly 11.0% of the nosocomial
isolates were resistant to this drug group in both regions. TMP-SMZ, ticarcillin–clavulanic acid, gatifloxacin, and
trovafloxacin were the only agents with consistent therapeutic activity against S. maltophilia isolates. Rates of
resistance to TMP-SMZ ranged from 2% in Canada and Latin America to 10% in Europe. The geographic
differences in resistance patterns among Acinetobacter species and S. maltophilia isolates observed in this study
emphasize the importance of local surveillance in determining the most adequate therapy for acinetobacter and
S. maltophilia infections and the possible clonal, epidemic nature of occurrence.
Acinetobacter species are ubiquitous organisms widely
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distributed in nature. These gram-negative bacilli are
usually commensal, but in the past few decades they
have emerged as important opportunistic pathogens,
especially in the nosocomial setting [1]. They are ca-
pable of causing a range of nosocomial infections, in-
cluding pneumonia, bacteremia, secondary meningitis,
urinary tract infections, and surgical wound infections.
In the United States, data collected by hospitals par-
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ticipating in the National Nosocomial Infection Surveillance
(NNIS) system during 1992–1997 showed that Acinetobacter
species caused 1% of nosocomial bloodstream infections (BSIs)
and 3% of pneumonia cases in the coronary care unit [2].
Acinetobacter was also reported as the seventh most common
genus of pathogens recovered from intensive care unit patients
in the European Prevalence of Infections in Intensive Care
study, accounting for 8% and 10% of all cases of BSI and
pneumonia, respectively [3]. Acinetobacter species isolates have
unique characteristics among nosocomial gram-negative bac-
teria that favor their persistence in the hospital environment.
They usually are resistant to the action of many antimicrobials,
spread easily from patient to patient, and are resistant to des-
iccation, thus persisting in the environment for many days.
This factor could explain their propensity for causing extended
epidemic outbreaks. Species other than Acinetobacter bauman-
nii are involved less frequently as causes of nosocomial infection
and generally are more susceptible to antimicrobials [1, 4–6].
Previous studies have reported that acinetobacter infections
are more prevalent in tropical countries and during the late
summer [7, 8]. Community-acquired acinetobacter infections
are relatively uncommon, although Anstey and colleagues re-
ported that 10.0% of cases of community-acquired pneumonia
in the Northern Territory of Australia were caused by Acine-
tobacter species [9]. In recent years, the increasing incidence of
carbapenem (imipenem, meropenem)–resistant Acinetobacter
strains has been noticed in several hospitals [10–14]. Therapy
for infections caused by such organisms is often problematic,
and usually the only antimicrobial agents available for therapy
are polymyxins and ampicillin/sulbactam.
Stenotrophomonas maltophilia, previously known as Pseu-
domonas maltophilia and then Xanthomonas maltophilia, is a
common commensal that is readily isolated from water, soil,
and sewage [15–18]. However, it has also emerged as an im-
portant opportunistic pathogen in immunocompromised hosts
such as patients undergoing transplantation or patients with
cancer [19]. S. maltophilia generally causes hospital-acquired
infections, but community-acquired infections have also been
reported. Although S. maltophilia isolates may cause a wide
spectrum of human diseases [20–27], the respiratory tract is
the most common site of S. maltophilia infection, especially in
patients with cystic fibrosis and others with compromised lung
function [28–30]. It has been suggested that the increase in the
incidence of S. maltophilia infections might be consequent to
selective pressure caused by overuse of broad-spectrum b-lac-
tams in the hospital environment or by individual patients
[31–33].
Like other nonfermentative species, S. maltophilia isolates
are intrinsically resistant to many commonly used antimicrobial
agents. They produce diverse drug-hydrolyzing enzymes such
as L1, a zinc-dependent metalloenzyme, and L2, a cephalos-
porinase, which are able to destroy important classes of b-
lactams such as carbapenems and cephalosporins, respectively
[34–36]. S. maltophilia isolates also quickly develop resistance
to fluoroquinolones by mutations in outer-membrane proteins.
Recently, Zhang and colleagues demonstrated the involvement
of efflux mechanisms in acquired multidrug resistance in S.
maltophilia [37]. Trimethoprim-sulfamethoxazole (TMP-SMZ)
has been the drug of choice for treatment of S. maltophilia
infections. Although TMP-SMZ has been shown to be the most
potent antimicrobial against this pathogen, resistance has
emerged [19, 24, 38–41].
The purpose of the present report is to establish the fre-
quency of occurrence of Acinetobacter species and S. maltophilia
infections by geographic region and body site of infection at
the participating institutions of the SENTRY Antimicrobial Sur-
veillance Program [42]. Comparative antimicrobial activity of
numerous antimicrobial agents against Acinetobacter species
and S. maltophilia isolates was evaluated, including an analysis
of imipenem-resistant Acinetobacter species and TMP-
SMZ–resistant S. maltophilia isolates. Seasonal variation in the
occurrence of acinetobacter BSIs was also assessed.
MATERIALS AND METHODS
Study design. The SENTRY Antimicrobial Surveillance Pro-
gram has monitored the predominant pathogens and antimi-
crobial resistance patterns in nosocomial and community-ac-
quired infections via a broad network of sentinel hospitals in
5 geographic regions: the Asia-Pacific, Europe, Latin America,
Canada, and the United States [42]. The monitored infections
include BSIs (objective A), outpatient respiratory tract infec-
tions due to specific fastidious organisms (objective B), pneu-
monia in hospitalized patients (objective C), skin/soft-tissue
infections (objective D), and urinary tract infections (objective
E). Consecutive isolates (∼540 strains/year for all objectives per
laboratory) were forwarded to the regional monitors for con-
firmation of organism identification and reference antimicro-
bial susceptibility testing. Since most of the isolates are collected
from nonsterile body sites, the participating medical centers
are encouraged to send only clinically significant isolates. Just
1 isolate per patient per site of infection was included in this
study. A summary of demographic data such as each patient’s
age, sex, and ward, hospitalization in the intensive care unit,
and whether the infection was nosocomial or community ac-
quired was also obtained.
Participating medical centers. The number of participat-
ing medical centers varied from 66 in 1997 to 81 in 1998. The
number varied slightly by year in the following regions: 5–8
sites in Canada, 26–28 in the United States, and 12–23 in Eu-
rope, Israel, and Turkey. The number of sites remained the
same in the Asia-Pacific region (17 sites) and Latin America
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Table 1. Total number of strains isolated and percentage of Acinetobacter species
strains observed, by site of infection, as reported in the SENTRY Antimicrobial Surveil-
lance Program by participating medical centers between January 1997 and December
1999.
Country or region
Occurrence by site of infection
Blood Respiratory Wound Urine
Canada
Total no. of isolates 3840 1659 633 651
Acinetobacter; % (range) 0.7 (0.5–1.0) 2.0 (1.4–3.9) 2.2 (2.0–2.4) 0.2 (0.0–0.4)
United States
Total no. of isolates 17,399 6711 2191 2569
Acinetobacter; % (range) 1.4 (0.9–1.7) 2.5 (2.3–2.8) 2.1 (2.0–2.2) 1.0 (0.9–1.0)
Latin America
Total no. of isolates 5295 1914 1353 1430
Acinetobacter; % (range) 4.6 (3.2–5.3) 9.7 (7.1–11.6) 4.7 (3.5–5.5) 2.2 (0.9–3.2)
NOTE. A total of 70,067 strains (1078 Acinetobacter species isolates) were analyzed over the 3 study
years. Ranges indicate occurrence rates over the 3 years monitored.
(10 sites). Three reference laboratories, with use of common
reagents and methodologies, evaluated the respective isolates:
University of Iowa College of Medicine (Iowa City, IA; isolates
from Canada, the United States, and Latin America for
1997–1999 and Europe for 1999); Women’s and Children’s
Hospital (Adelaide, Australia; isolates from the Asia-Pacific re-
gion for 1998–1999); and Utrecht University (Utrecht, The
Netherlands; isolates from Europe for 1997–1998).
Bacterial strains. A total of 70,067 bacterial isolates were
collected between January 1997 and December 1999. This num-
ber did not include isolates collected in association with ob-
jective B. Isolates collected from urinary tract and skin/soft-
tissue infections in Canada, Europe, and the United States
during 1999 were not included because of a change in the
protocol design that affected prevalence data. During the study
period, 1078 Acinetobacter species isolates and 842 S. malto-
philia isolates were observed. In this study, only Acinetobacter
species isolates collected from Canada, Latin America, and the
United States were studied. The Acinetobacter data from the
Asian-Pacific and European regions will be further analyzed.
Organism identification. All isolates were identified at the
participating institution by the routine methodology in use at
each laboratory. Upon receipt at the monitoring laboratory,
isolates were subcultured onto blood agar to ensure viability
and purity. Confirmation of species identification was per-
formed with the Vitek system (bioMe´rieux Vitek) or conven-
tional methods as required.
Susceptibility testing. At the monitoring laboratory, an-
timicrobial susceptibility testing was performed with use of the
reference broth microdilution method, as described by the Na-
tional Committee for Clinical Laboratory Standards (NCCLS)
[43]. The MICs were defined as the lowest antimicrobial con-
centrations able to totally inhibit bacterial growth. Antimicro-
bial agents were obtained from the respective manufacturers.
These agents included piperacillin, piperacillin-tazobactam, ti-
carcillin, ticarcillin–clavulanic acid, ceftazidime, cefepime, im-
ipenem, meropenem, ciprofloxacin, levofloxacin, gatifloxacin,
trovafloxacin, amikacin, gentamicin, tobramycin, tetracycline,
and TMP-SMZ. Numerous other compounds were tested but
were not described here because of limited potency. Quality
control was performed by testing Escherichia coli ATCC 25922,
Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa
ATCC 27853, and Enterococcus faecalis ATCC 29212. All quality-
control findings among reported data were within ranges pub-
lished by the NCCLS [43].
RESULTS AND DISCUSSION
Acinetobacter species distribution and infection sites. De-
spite the limitation of commercial systems for identification of
the genus Acinetobacter at the species level, A. baumannii was
the most commonly reported species in the 3 geographic
regions evaluated in this report. Among Latin American iso-
lates, the 3 most frequent species isolated were A. baumannii
(75.0%), Acinetobacter anitratus (8.2%), and Acinetobacter spe-
cies (7.4%), whereas in Canada and the United States the most
frequently isolated were A. baumannii (54.6%), A. anitratus
(14.8%), and A. calcoaceticus (14.6%). These data agree with
those from previous studies [6, 44], which showed A. bau-
mannii as the most frequent species. Among the nosocomial
isolates, the 3 most frequent species were A. baumannii 1 A.
anitratus 1 A. calcoaceticus in both regions. However, among
the community-acquired isolates, A. lwoffii was the second and
third most frequent species in Canada/United States and Latin
America, respectively.
The distribution of Acinetobacter isolates by body site is
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Table 2. Distribution by age and sex of patients in Latin
America, Canada, and the United States with infections
caused by Acinetobacter species, as reported in the SEN-
TRY Antimicrobial Surveillance Program by participating
medical centers between January 1997 and December 1999.
Age,
years
No. (%) of patients infected
Latin America
Canada and
United States
Female Male Female Male
!1 6 (3.3) 11 (3.6) 8 (3.7) 19 (5.6)
1–10 9 (5.0) 10 (3.3) 21 (9.6) 20 (5.9)
11–20 4 (2.2) 12 (3.9) 15 (6.9) 23 (6.8)
21–30 17 (9.5) 25 (8.2) 17 (7.8) 35 (10.3)
31–40 13 (7.3) 33 (10.8) 21 (9.6) 45 (13.3)
41–50 23 (12.8) 36 (11.8) 28 (12.8) 41 (12.2)
51–60 25 (14.0) 52 (17.1) 22 (10.0) 51 (15.1)
61–70 31 (17.3) 46 (15.1) 37 (17.0) 45 (13.3)
71–80 34 (19.0) 55 (18.1) 31 (14.2) 44 (13.0)
180 17 (9.5) 24 (7.9) 18 (8.2) 14 (4.1)
Total 179 304 218 337
Table 3. Number and percentage of Acinetobacter spe-
cies strain isolations, by medical service, as reported in
the SENTRY Antimicrobial Surveillance Program by partic-
ipating medical centers between January 1997 and De-
cember 1999.
Service
No. (%) of isolates
Latin America
Canada and
United States
Internal medicine 302 (73.5) 179 (50.0)
Surgery 30 (7.3) 74 (20.7)
Intensive care unit 38 (9.2) 53 (14.8)
Pediatrics 31 (7.5) 29 (8.1)
Gynecology and obstetrics 2 (0.5) 2 (0.5)
Emergency 5 (1.2) 17 (4.7)
Transplantation 3 (0.7) 4 (1.1)
shown in table 1. The statistics for Canada and the United
States show that Acinetobacter isolates were frequently recovered
from wounds (2.0%–2.4%) and respiratory tract infections
(1.4%–3.9%), whereas in Latin America the respiratory tract
was clearly the most common body site of infections
(7.1%–11.6%). In Latin America, respiratory Acinetobacter spe-
cies isolates were 2-fold more frequent than wound isolates
( ). The greater frequency of acinetobacter infections inP ! .001
Latin America than in all other SENTRY regions was highly
significant ( ; isolated 2–10 times more often). Per-P ! .001
centages of Acinetobacter species isolates causing BSIs were sim-
ilar to those previously reported from the SENTRY and Sur-
veillance and Control of Pathogens of Epidemiologic
Importance programs [42, 44], in which these microorganisms
accounted for 1.6% of all BSIs in Canada/United States and
for 5.3% in Latin America.
Patient and hospital demographics of acinetobacter infec-
tions. The number of acinetobacter infections increased lin-
early with age from 11 to 80 years for both sexes and in the
geographic locations monitored. A higher prevalence rate was
noted from birth to age 10 years (6.9%–13.3%), especially
among infants !1 year of age (3.3%–5.6% of all cases), re-
gardless of sex or geographic area (table 2). In contrast, a decline
in the number of infections among patients 181 years of age
was observed. Approximately 61.0% and 63.0% of acinetobac-
ter infections were in male patients in Canada/United States
and Latin America, respectively ( ).P ! .0001
The distribution of acinetobacter infections by medical ser-
vice is shown in table 3. Most cases occurred in the internal
medicine service in both regions. In Canada/United States, sur-
gical units were the second most frequent contributors of Aci-
netobacter species isolates. However, the percentage of acine-
tobacter infections was higher in intensive care units than in
surgery services in Latin America. This finding might indicate
the presence of endemic clones in intensive care units [45].
Recently, Wisplingghoff and colleagues reported that A. bau-
mannii BSIs occurred more frequently in intensive care units
[44]. No differences in the distribution of isolates of Pseudo-
monas aeruginosa (another nonfermentative pathogen) by med-
ical service were noted between Latin America and Canada/
United States in the SENTRY program (data not shown).
Among the acinetobacter infections in Latin America, nearly
60.0% were nosocomial. This trend was not observed in the
Canada/United States region, where Acinetobacter strains were
equally distributed among nosocomial and community-ac-
quired infections. However, the mode of acquisition of aci-
netobacter infections was unknown in 44.0% of cases in this
geographic region.
Antimicrobial susceptibility of Acinetobacter species iso-
lates. Tables 4 and 5 list the activity of 15 selected antimi-
crobial agents tested against all Acinetobacter strains. Generally,
isolates from Canada/United States (table 4) were more sus-
ceptible to all recorded drugs than were those from Latin Amer-
ica (table 5). Some of the most notable differences between
these respective regions in terms of susceptibility to the anti-
microbials tested were as follows: ceftazidime, 67.0% vs. 25.9%;
piperacillin/tazobactam, 68.5% vs. 25.0%; ciprofloxacin, 69.6%
vs. 29.7%; amikacin, 87.5% vs. 32.2%; and tetracycline, 70.7%
vs. 57.1%. Only the carbapenems remained highly active in
both areas (89.0% and 95.5% susceptibility, respectively).
In Canada/United States, nosocomial isolates were signifi-
cantly more resistant to b-lactams than were community-ac-
quired isolates (data not shown) or all isolates tested (P !
). In contrast, in Latin America the resistance rates of no-.001
socomial and all isolates were very similar for all drug classes.
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Table 4. Activity of 15 selected antimicrobial agents tested against nosocomial and all Acinetobacter species
strains isolated in the SENTRY Antimicrobial Surveillance Program in the United States and Canada between
January 1997 and December 1999.
Antimicrobial agent
Nosocomial isolates (n p 150) All reported isolates (n p 552)a
MIC; mg/mLb Test result; %c MIC; mg/mLb Test result; %c
MIC50 MIC90 Susceptible Resistant MIC50 MIC90 Susceptible Resistant
Ticarcillin 16 1128 54.7 28.7 16 1128 62.3 15.3
Ticarcillin–clavulanic acid 16 1128 62.7 18.0 16 128 69.1 12.5
Piperacillin 32 1128 45.3 28.0 16 1128 50.9 23.0
Piperacillin/tazobactam 16 164 62.7 20.7 8 164 68.5 15.7
Ceftazidime 116 116 65.3 24.0 8 116 67.0 19.8
Cefepime 16 116 67.3 19.3 4 116 67.5 18.8
Imipenem 0.25 8 88.0 8.0 0.25 18 95.5 3.0
Meropenem 0.5 18 87.3 10.7 0.5 18 94.1 4.1
Ciprofloxacin 0.25 12 70.0 28.0 0.25 12 69.6 27.1
Gatifloxacinb 0.12 14 76.0 20.0 0.12 14 75.0 21.3
Trovafloxacin 0.03 14 78.7 12.0 0.03 14 75.4 22.7
Amikacin 4 16 91.3 4.0 4 32 87.5 8.2
Gentamicin 1 18 71.3 25.3 2 18 70.9 26.2
Tobramycin 1 16 85.3 12.0 1 18 79.6 16.4
Tetracycline 4 18 70.7 20.7 4 18 70.7 22.3
a Includes only 151 strains of community-acquired Acinetobacter species.
b MICs determined by broth microdilution, as described by the National Committee for Clinical Laboratory Standards (2000guidelines).
c Percentages of susceptibility and resistance determined by NCCLS interpretive criteria (2000 guidelines) or as follows: gatifloxacin,
susceptible at 2 mg/mL and resistant at 8 mg/mL (product package insert).
Therefore, the rank order for resistance among Acinetobacter
isolates was as follows: Latin America nosocomial isolates p
Latin America total isolates 1 North America nosocomial iso-
lates 1 North America total isolates or community-acquired
isolates.
The best drugs for therapy in North America were imipenem
(88.0%–95.5% susceptible) and meropenem (87.3%–94.1%
susceptible) among the b-lactams, gatifloxacin (75.0%–76.0%
susceptible) among the clinically usable fluoroquinolones, ami-
kacin (87.5%–91.3% susceptible) among the aminoglycosides,
and tetracyclines (70.7% susceptible). In Latin America (table
5), only the carbapenems inhibited 180% of strains. Tetracy-
cline showed the second highest susceptibility rate, inhibiting
57.1%–58.8% at 4 mg/mL. Although tobramycin was more
active than amikacin against Acinetobacter species isolated in
Latin America, only 42.1%–46.6% were susceptible at its limits
of susceptibility. The newer fluoroquinolones, gatifloxacin and
trovafloxacin, were slightly superior to ciprofloxacin in the
spectrum of potential clinical uses against Acinetobacter. Com-
parison of these results with those previously published revealed
a trend toward increasing incidence of antimicrobial resistance
among Acinetobacter isolates [42, 46, 47].
Occurrences of carbapenem-resistant Acinetobacter spe-
cies. The distribution of carbapenem (imipenem)–non-
susceptible Acinetobacter species (INSA) by geographic region
and body site of infection is shown in table 6. The occurrence
of these INSA isolates was higher in Latin America (11.4%)
than in the United States (4.8%) or Canada (2.7%). Latin
America contributed more INSA isolates than Canada/United
States (P ! .0001). Although the United States had more iso-
lations than Canada, the difference was not statistically signif-
icant. In the United States and Canada, few sites (6%) regularly
recovered INSA isolates, whereas in Latin America the majority
of reporting medical centers isolated these resistant strains. It
is notable that each of the medical centers in Canada contrib-
uted 1 isolate only. In the United States, the INSA strains were
isolated in only 2 medical centers, located in New York. The 6
medical centers in Latin America were located in Argentina,
Chile, Colombia, Mexico, Brazil, and Venezuela, and 3 sites had
epidemic clusters (table 6); a single Brazilian institution con-
tributed nearly one-half of the INSA isolates.
Nearly 70% of INSA isolates were A. baumannii. The dis-
tribution of these isolates by body site was the same in all
regions evaluated, with respiratory isolates being slightly more
frequent than BSI strains (difference not statistically signifi-
cant). Seventy-four percent and 60% of INSA isolates were
nosocomial in the United States and Latin America, respec-
tively. Among infections caused by these isolated strains, 57%
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Figure 1. Occurrences of acinetobacter bloodstream infections (BSIs),
by month of isolation of the organism in the SENTRY program (1997–1999)
and by geographic region.
Table 5. Activity of 15 selected antimicrobial agents tested against nosocomial and all Acinetobacter species
strains isolated in the SENTRY Antimicrobial Surveillance Program in Latin America between January 1997 and
December 1999.
Antimicrobial agent
Nosocomial isolates (n p 311) All isolates (n p 526)a
MIC; mg/mLb Test result; %c MIC; mg/mLb Test result; %c
MIC50 MIC90 Susceptible Resistant MIC50 MIC90 Susceptible Resistant
Ticarcillin 1128 1128 19.9 70.8 1128 1128 19.8 70.8
Ticarcillin–clavulanic acid 1128 1128 24.1 61.4 1128 1128 24.0 60.5
Piperacillin 1128 1128 17.0 72.9 1128 1128 17.1 73.9
Piperacillin/tazobactam 64 164 25.7 49.8 164 164 25.0 51.2
Ceftazidime 116 116 24.1 65.6 116 116 25.9 63.6
Cefepime 16 116 35.4 45.7 16 116 34.3 43.8
Imipenem 1 18 88.4 10.3 1 8 88.6 9.9
Meropenem 1 18 88.7 10.6 1 8 89.0 9.7
Ciprofloxacin 12 12 30.9 68.5 12 12 29.7 69.9
Gatifloxacinb 4 14 36.0 45.0 4 14 34.3 46.5
Trovafloxacin 14 14 38.4 60.6 14 14 36.7 62.2
Amikacin 132 132 31.5 64.8 132 132 32.2 62.5
Gentamicin 18 18 34.7 58.1 18 18 33.5 60.6
Tobramycin 8 116 46.6 48.1 16 116 42.1 52.9
Tetracycline 4 18 58.8 20.9 4 18 57.1 22.1
a Includes only 63 strains of community-acquired Acinetobacter species.
b MICs determined by broth microdilution, as described by the National Committee for Clinical Laboratory Standards (2000
guidelines).
c Percentages of susceptibility and resistance determined by NCCLS interpretive criteria (2000 guidelines) or as follows: gatifloxacin,
susceptible at 2 mg/mL and resistant at 8 mg/mL (product package insert).
and 52% required intensive care unit hospitalization in Latin
America and the United States, respectively. In the United
States, amikacin (MIC50, 4 mg/mL) and tobramycin (MIC50, 1
mg/mL) were the only drugs that had good in vitro activity
against the INSA strains, inhibiting 95.7% and 69.6% of these
isolates, respectively (data not shown). In contrast, in Latin
America, no drug had acceptable activity. Although tetracycline
and gatifloxacin were the best antimicrobials tested against such
isolates, they inhibited !40% of the INSA isolates. Ampicillin/
sulbactam and the polymyxins are the only possible options
currently available for treatment of such infections.
The activities of polymyxin B and colistin were tested by
broth microdilution against 60 bloodstream Acinetobacter iso-
lates collected from diverse SENTRY Program medical sites in
1998. Approximately 20.0% of these samples were nonsuscep-
tible to imipenem. Ninety percent of these strains were inhib-
ited by very low concentrations of polymyxin B (2 mg/mL or
16 U) and colistin (2 mg/mL). In contrast to findings in other
studies [10, 48], 3 Acinetobacter isolates with reduced suscep-
tibility to polymyxins (MICs, 8 mg/mL) were detected. This
indicates that polymyxins might not be completely active
against Acinetobacter species.
Seasonal characteristics of acinetobacter infections. Fig-
ure 1 shows the seasonal variation of Acinetobacter species in-
fections. Only bloodstream isolates were included for this eval-
uation of acinetobacter infections since they were collected year
round rather than during a specific period of time, as occurs
for other SENTRY objectives. In Latin America (1997), the
highest number of acinetobacter infections occurred during the
summer. However, in 1998, the opposite seasonal occurrence
 at Escola Paulista M
edicina on O
ctober 15, 2015
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
S110 • CID 2001:32 (Suppl 2) • Gales et al.
Table 6. Distribution of imipenem-nonsusceptible Acinetobacter species strains,
by geographic location and body site of infection, in the SENTRY Antimicrobial
Surveillance Program, 1997–1999.
Region
No. of medical
centers reporting
imipenem-nonsusceptible
isolates
Site of infection, no. of isolates
Blood Respiratory Wound Urine
Canada 2 1 1 0 0
Latin America 6a 24 26 9 0
United States 2b 9 9 5 0
a Epidemic clusters detected in 3 medical centers, in Argentina, Brazil, and Venezuela.
b Epidemic clusters detected in 2 medical centers.
Table 7. Frequency of occurrence of Stenotrophomonas mal-
tophilia isolates in the SENTRY Antimicrobial Surveillance
Program, indexed by geographic region, site of infection, and
year of isolation (1997–1999).
Region
Source of
isolate
Occurrence by year,
% of isolates
1997 1998 1999 Overall
Asia-Pacific Blood NT 1.3a 0.4 0.9
Respiratory NT 2.9 2.7 2.8
Wound NT 0.2 0.0 0.1
Urine NT 0.3 0.0 0.2
Canada Blood 0.6 0.5 0.6 0.6
Respiratory 4.7b 6.1b 4.8b 5.2b
Wound 1.8c 0.4 NTd 1.1
Urine 0.0 0.0 NT 0.0
Europe Blood 1.1a 0.7 1.0a 0.9
Respiratory 2.9 2.5 4.1 3.2
Wound 0.7 0.5 NT 0.6
Urine 0.1 0.2 NT 0.2
Latin America Blood 0.9 0.8 0.7 0.8
Respiratory 2.3 2.0 1.2 1.8
Wound 0.9 0.2 0.0 0.4
Urine 0.0 0.0 0.0 0.0
United States Blood 0.7 0.7 0.6 0.7
Respiratory 3.5 3.7 2.7 3.3
Wound 0.7 1.4c NT 1.0
Urine 0.5d 0.1 NT 0.3
NOTE. NT, not tested in a prevalence study format.
a Highest rate of bloodstream infections, across all regions and time
periods.
b Highest rates of S. maltophilia pneumonia were reported fromCanada.
c Significantly higher rates of wound infection were associated with S.
maltophilia.
d Urinary tract infection rate 5-fold greater than the overall SENTRY
program rate of occurrence (!0.1%).
was observed, with many cases detected during the winter. In
1999 the highest number of cases involving Acinetobacter spe-
cies was observed during the winter, heavily influenced by an
outbreak in one of the Brazilian medical centers. In the Canada/
United States during 1997, the highest number of cases oc-
curred in the winter. In 1998, 2 peaks of high isolation rates
occurred, 1 in the summer and the other during the fall. Nearly
50% of the cases reported during the fall were at 3 different
hospitals and represent small epidemic clusters. In 1999 the
highest percentage of cases occurred during the summer, rep-
resenting a seasonal increase in the incidence of acinetobacter
infection that has been previously reported [7, 8].
McDonald et al. [8] analyzed acinetobacter infection rates
reported to the NNIS system from 1987 through 1996 and
found a persistent seasonal increase during the late summer
months. The reasons for this phenomenon are unclear, but they
may be related to increased ambient humidity favorable for this
organism’s growth. Many reasons could account for the lack
of this pattern in Latin America, such as the persistence of
endemic strains in some medical centers, allowing the occur-
rence of clustered epidemic acinetobacter infections throughout
the year, or an insufficient number of strains collected monthly
in the SENTRY program to clarify seasonal prevalence.
Occurrence of S. maltophilia infections. Table 7 lists the
frequency of occurrence of S. maltophilia isolates by geographic
region, site of infection, and year of isolation. In the SENTRY
program, the respiratory tract was the most commonly reported
S. maltophilia infection site in all geographic regions. Pneu-
monia-causing S. maltophilia isolates were 4-fold more prev-
alent than BSI isolates (3.3% of all isolates). The SENTRY rates
by geographic area per year for isolations of S. maltophilia in
cases of pneumonia varied from 1.2% to 4.8%. The highest
rates were detected in Canada (4.7%, 4.8%, and 6.1% in 1997,
1998, and 1999, respectively), and these values were associated
with epidemic occurrences in some of the monitored institu-
tions. The prevalence of S. maltophilia in BSIs was only
0.4%–1.3% of cases among all SENTRY program geographic
regions and years (average, 0.8% of cases overall). The highest
BSI occurrences were seen in Asia-Pacific (1.3% in 1998) and
Europe (1.0% and 1.1% in 1999 and 1997, respectively). In a
previous report on this study [42], S. maltophilia accounted
for 0.6%–0.9% of all BSIs reported from the United States,
Canada, and Latin America. Wound and urinary tract infections
caused by S. maltophilia remain more rare (1.1%).
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Table 8. Antimicrobial activity of 10 selected compounds tested against Stenotrophomonas
maltophilia strains from 5 continents (n p 842) in the SENTRY Antimicrobial Surveillance
Program, 1997–1999.
Antimicrobial agent
Resistance, % of isolates (range for monitored years)
Asia-Pacific
(n p 80)
Canada
(n p 119)
Europe
(n p 192)
Latin America
(n p 83)
United States
(n p 368)
TMP-SMZ 8 (4–11) 2 (0–6) 10 (3–19) 2 (0–6) 5 (0–9)
Ticarcillin–clavulanate 29 (25–32) 15 (12–18) 14 (7–27) 13 (9–21) 10 (8–13)
Piperacillin/tazobactam 73 (70–75) 40 (30–53) 43 (23–66) 41 (9–63) 47 (42–53)
Ceftazidime 53 (48–58) 40 (33–49) 28 (10–49) 25 (16–32) 33 (33–34)
Amikacin 81 (71–91) 81 (67–92) 45 (12–88) 74 (66–88) 79 (64–91)
Tobramycin 87 (83–91) 81 (67–89) 53 (26–88) 82 (66–91) 85 (75–94)
Ciprofloxacin 49 (43–54) 53 (43–62) 21 (10–42) 43 (41–47) 45 (37–50)
Gatifloxacin 13 (4–21) 15(6–24) 2 (0–5) 6 (5–6) 7 (5–10)
Trovafloxacin 13 (5–21) 12 (6–16) 2 (0–5) 7 (5–9) 10 (7–12)
Tetracycline 75 (70–79) 61 (41–73) 49 (30–81) 49 (38–58) 55 (45–70)
NOTE. TMP-SMZ, trimethoprim/sulfamethoxazole.
The antimicrobial activities of 10 selected compounds against
842 S. maltophilia strains collected from the 5 continents are
shown in table 8. Against S. maltophilia, the activity and spec-
trum of few antimicrobial drugs are acceptable for treatment.
Most of the isolates discovered in this study were susceptible
to TMP-SMZ and ticarcillin–clavulanic acid. These data agree
with those from previous studies [38, 40]. Overall, rates of
resistance to the “drug of choice” (TMP-SMZ) ranged from
2% in Canada and Latin America to 10% in Europe (range
during study period, 3%–19%). Several other investigators have
reported resistance to TMP-SMZ [19, 24, 40, 41, 49]. Other
drugs of potential therapeutic value also had high resistance
rates: ticarcillin–clavulanic acid, 10%–29% resistance; gatiflox-
acin, 2%–15%; and trovafloxacin, 2%–13%.
Fluoroquinolones have been considered a possible option for
treatment [31, 41], although ciprofloxacin-resistant mutants of
S. maltophilia can be easily selected in vitro. In this study, the
activity of the newest fluoroquinolones was enhanced in com-
parison with that of ciprofloxacin, thus confirming results of
previous studies [40, 50, 51]. The gatifloxacin resistance rate
among all S. maltophilia isolates ranged from only 2% (Europe)
to 15% (Canada). This study also confirms previous reports
that ticarcillin–clavulanic acid is the most active b-lactam [40,
41].
Strains of S. maltophilia isolated in the Asia-Pacific region
tended to be more resistant, especially to b-lactams and tet-
racycline. Aminoglycosides were most likely to be useful in
Europe, but a wide variation between centers was noted. Eu-
ropean isolates also had the lowest rates of fluoroquinolone
resistance.
Table 9 summarizes various additional details concerning the
69 S. maltophilia strains that were resistant to TMP-SMZ. The
majority (77%) of these strains were isolated in the United
States and Europe from male patients (59%) with pneumonia
or BSI. Marked genetic diversity was noted among the strains,
which came from 43 contributing medical centers. Only 2 ep-
idemic clusters, involving 5 strains from 1 site, were docu-
mented by ribotyping and pulsed-field gel electrophoresis. The
average patient age ranged from 48 years in Europe to 80 years
in Latin America.
CONCLUSIONS
Nonfermentative gram-negative bacilli, especially Acinetobacter
strains, represent a real problem in certain geographic regions
such as Latin America, where these strains are routinely more
resistant to antimicrobial agents. These elevated resistance rates
may be consequent to the differences in antimicrobial usage,
infection-control practices, and climate [52]. Previous resis-
tance surveillance studies have also demonstrated geographic
differences in the antimicrobial susceptibility patterns of Aci-
netobacter species isolates [42, 53]. With Acinetobacter species
isolates rapidly developing resistance to currently available an-
timicrobials, the development of new agents is extremely im-
portant, as is seeking the best agents among older compounds.
Since no novel antimicrobial drugs for use against gram-neg-
ative bacilli are available, polymyxins and sulbactam in many
cases are the only therapeutic options for treatment of multid-
rug-resistant acinetobacter infections.
Epidemic clusters of carbapenem-resistant strains were de-
tected in some participating centers in the SENTRY program
(3 in Latin America and 2 in the United States). This indicates
that infection-control policies must be reviewed in the respec-
tive institutions and infection-control interventions must be
initiated to decrease the number of serious acinetobacter
infections.
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Table 9. Location and characteristics of trimethoprim/sulfamethoxazole-resistant S. maltophilia
strains in the SENTRY Antimicrobial Surveillance Program, 1997–1999.
Region (no. of strains)
No. of
medical
centers
No. of isolations, by site of infection
Average
patient
age, years
Male
sex,
%Blood Respiratory Wound Urine
Asia-Pacific (n p 9) 7 5 4 0 0 64 78
Canada (n p 4) 3 0 4 0 0 74 100
Europe (n p 25) 14 12 8 3 2 48 52
Latin America (n p 3) 3 2 1 0 0 80 67
United States (n p 28) 16a 9 16 3 0 54 56
Total (n p 69) 43 28 33 6 2 55 59
a Two epidemic clusters in 1 hospital (5 strains).
Over the past 15 years, infections due to multidrug-resistant
S. maltophilia have also emerged as important nosocomial in-
fections in many institutions. This fact is in part attributable
to the increasing number of immunocompromised patients as
well as the increasing use of broad-spectrum b-lactam agents
and assisted-ventilation techniques. This report confirms that
S. maltophilia remains highly resistant to various classes of an-
timicrobials and demonstrates that TMP-SMZ, ticarcil-
lin–clavulanic acid, gatifloxacin, and trovafloxacin are among
the only agents suitable for treatment of such infections, either
alone or in combinations.
Epidemic occurrences of S. maltophilia and Acinetobacter
species appear to be increasing. In the SENTRY program, ep-
idemic clusters of pneumonia and BSI were detected in some
of the participating medical centers. Also, an increasing trend
in the incidence of respiratory tract infections due to S. mal-
tophilia was observed in Europe (from 2.5% in 1998 to 4.1%
in 1999) for this study interval. Unfortunately, the intrinsic
resistance of this organism to many antimicrobials and the
rapid selection of high-level multidrug-resistant isolates in clin-
ical strains pose a continuing problem for treatment as well as
infection control.
The SENTRY Antimicrobial Surveillance Program results
have documented the wide variations in the prevalence and
antimicrobial susceptibility of 2 important gram-negative no-
nenteric bacilli, Acinetobacter species and S. maltophilia. Be-
cause of the emerging complex resistance patterns found in
these organisms and the difficulty of therapy, surveillance pro-
grams will be increasingly necessary to monitor the spread of
resistant clones, to guide local interventions, and to be a testing
arena for novel antimicrobial agents.
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